Daré Bioscience (DARE) Competitors $3.34 +0.01 (+0.30%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends DARE vs. ANRO, IVA, NVCT, DBVT, TARA, INZY, MGX, ELUT, ENTA, and IGMSShould you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Alto Neuroscience (ANRO), Inventiva (IVA), Nuvectis Pharma (NVCT), DBV Technologies (DBVT), Protara Therapeutics (TARA), Inozyme Pharma (INZY), Metagenomi (MGX), Elutia (ELUT), Enanta Pharmaceuticals (ENTA), and IGM Biosciences (IGMS). These companies are all part of the "pharmaceutical products" industry. Daré Bioscience vs. Alto Neuroscience Inventiva Nuvectis Pharma DBV Technologies Protara Therapeutics Inozyme Pharma Metagenomi Elutia Enanta Pharmaceuticals IGM Biosciences Daré Bioscience (NASDAQ:DARE) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Does the MarketBeat Community favor DARE or ANRO? Daré Bioscience received 343 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 82.35% of users gave Alto Neuroscience an outperform vote while only 73.31% of users gave Daré Bioscience an outperform vote. CompanyUnderperformOutperformDaré BioscienceOutperform Votes35773.31% Underperform Votes13026.69% Alto NeuroscienceOutperform Votes1482.35% Underperform Votes317.65% Does the media prefer DARE or ANRO? In the previous week, Daré Bioscience had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 1 mentions for Daré Bioscience and 0 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.00 beat Daré Bioscience's score of -1.00 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Overall Sentiment Daré Bioscience Negative Alto Neuroscience Neutral Which has stronger valuation & earnings, DARE or ANRO? Daré Bioscience has higher revenue and earnings than Alto Neuroscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDaré Bioscience$2.81M10.34-$30.16M-$0.59-5.65Alto NeuroscienceN/AN/A-$36.31MN/AN/A Do analysts recommend DARE or ANRO? Daré Bioscience currently has a consensus target price of $24.00, indicating a potential upside of 618.56%. Alto Neuroscience has a consensus target price of $20.00, indicating a potential upside of 335.26%. Given Daré Bioscience's higher possible upside, equities analysts plainly believe Daré Bioscience is more favorable than Alto Neuroscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daré Bioscience 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.63 Is DARE or ANRO more profitable? Alto Neuroscience has a net margin of 0.00% compared to Daré Bioscience's net margin of -191.65%. Daré Bioscience's return on equity of 0.00% beat Alto Neuroscience's return on equity.Company Net Margins Return on Equity Return on Assets Daré Bioscience-191.65% N/A -18.98% Alto Neuroscience N/A -49.28%-33.52% Do insiders and institutionals hold more shares of DARE or ANRO? 6.7% of Daré Bioscience shares are held by institutional investors. 4.0% of Daré Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryDaré Bioscience beats Alto Neuroscience on 9 of the 14 factors compared between the two stocks. Get Daré Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDaré BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.06M$6.50B$5.34B$9.12BDividend YieldN/A2.95%5.37%4.01%P/E RatioN/A4.3657.4613.13Price / Sales10.34310.771,272.2275.82Price / CashN/A22.8736.6632.72Price / Book-5.484.964.884.58Net Income-$30.16M$154.90M$118.05M$224.83M7 Day PerformanceN/A1.35%1.45%2.37%1 Month Performance23.25%0.41%2.50%4.40%1 Year Performance-10.22%3.08%25.79%20.10% Daré Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDaré Bioscience1.2681 of 5 stars$3.34+0.3%$24.00+618.6%-10.2%$29.06M$2.81M0.0030News CoverageNegative NewsANROAlto Neuroscience2.5969 of 5 stars$4.28-1.6%$20.00+367.3%N/A$115.43M$210,000.000.00N/AGap DownIVAInventiva2.6351 of 5 stars$2.17flat$13.25+510.6%-43.6%$113.88M$15.62M0.00100Positive NewsNVCTNuvectis Pharma2.9906 of 5 stars$5.81flat$21.00+261.4%-33.0%$112.26MN/A-5.018Positive NewsDBVTDBV Technologies3.609 of 5 stars$5.41+8.9%$22.50+315.9%-46.1%$111.28M$15.73M-1.2080TARAProtara Therapeutics2.541 of 5 stars$5.31-4.5%$22.67+326.9%+138.2%$109.55MN/A-1.8830INZYInozyme Pharma3.4605 of 5 stars$1.70-15.0%$18.33+978.4%-68.4%$109.21MN/A-1.0950Short Interest ↑Gap UpMGXMetagenomi1.6562 of 5 stars$2.91-7.0%$16.67+472.7%N/A$108.90M$55.08M0.00236Positive NewsGap DownELUTElutia3.1088 of 5 stars$3.14-3.7%$10.00+218.5%-19.8%$108.53M$24.78M-1.20180ENTAEnanta Pharmaceuticals4.1067 of 5 stars$5.03-1.2%$17.25+242.9%-55.2%$106.61M$67.64M-0.92160Positive NewsGap DownIGMSIGM Biosciences4.6968 of 5 stars$1.78-14.8%$5.50+209.0%-83.2%$105.85M$2.92M-0.49190Gap Up Related Companies and Tools Related Companies Alto Neuroscience Alternatives Inventiva Alternatives Nuvectis Pharma Alternatives DBV Technologies Alternatives Protara Therapeutics Alternatives Inozyme Pharma Alternatives Metagenomi Alternatives Elutia Alternatives Enanta Pharmaceuticals Alternatives IGM Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DARE) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daré Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daré Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DARE Stock Alerts